GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (6)
  • Cho, Sun Wook  (6)
Material
Publisher
  • American Association for Cancer Research (AACR)  (6)
Language
Years
Subjects(RVK)
  • 1
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 25, No. 1 ( 2019-01-01), p. 414-425
    Abstract: Thyroid-stimulating hormone (TSH) suppression is widely used to treat well-differentiated thyroid cancer, whereas its role in poorly differentiated thyroid cancer (PDTC) is undetermined. Besides thyrocytes, TSH also binds to stromal cells, comprising tumor microenvironments. This study aimed to investigate the effects of TSH on tumor microenvironments in PDTC. Experimental Design: An ectopic tumor model using PDTC cells (BHP10-3SCp and FRO), which exhibit TSH/cAMP-independent cell growth, was treated with TSH. IHC was performed using tissue microarrays from 13 PDTCs. Results: TSH treatment significantly enhanced tumor growth of PDTCs with increased vascularity but not that of breast cancer cells, suggesting this effect is unique to thyroid cancer cells, not stromal cells. TSH significantly upregulated VEGF-A and CXCL8 expressions in BHP10-3SCp cells via AKT and ERK signaling, resulting in higher concentrations of VEGF-A and CXCL8 in conditioned medium of TSH-treated BHP10-3SCp cells (TSH-CM) compared with controls. TSH-CM treatment enhanced tube formation potentials of endothelial cells, and blocking VEGF and/or CXCL8 reduced them. Blocking VEGF and/or CXCL8 also reduced TSH-dependent tumor growth with reduced tumor vasculature in vivo. TSH-treated tumors showed increased macrophage densities, and macrophage inhibition reduced TSH-dependent tumor growth in vivo. In human PDTCs, preoperative TSH levels were positively associated with VEGF-A and tumor size, and the expression of VEGF-A was positively correlated with CD31, CD163, and CXCL8, and their clinical poor prognosis. Conclusions: Aberrant TSH receptor signaling modulates tumor angiogenesis by stimulating VEGF-A and CXCL8 secretion from PDTC cells and enhances tumor growth; thus, TSH suppression is beneficial for treating PDTCs.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2019
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 82, No. 12_Supplement ( 2022-06-15), p. 5556-5556
    Abstract: CXCL16, as a chemotactic cytokine, has been observed in various human solid cancers. The effects of CXCL16 on tumor behavior is controversial and showed tissue-specific manners. In breast cancers, previous studies have showed that CXCL16 mainly originated from mesenchymal stromal cells or cancer-associated fibroblasts and played pro-tumorigenic roles. CXCL16 is highly expressed in triple-negative breast cancers (TNBC) in TCGA dataset for breast cancer. This study aimed to investigate the therapeutic effects of CXCL16 neutralizing antibody and its mechanisms in TNBC. To establish a xenograft mouse model of TNBC, MDA-MB-231 cells were injected subcutaneously to athymic nude mice, and mice were randomized into anti-CXCL16 and control groups. When measurable tumors were established, anti-CXCL16 neutralizing antibody (CLS-A101, cellus inc.) or control IgG were intravenously injected. Tumor growth was significantly delayed in the anti-CXCL16 group than the control group by 67% for 3 weeks. Flow cytometric analysis showed that macrophages (CD11b+F4/80+ cells) and myeloid derived suppressor cells (MDSC, CD11b+GR1+ cells) were decreased in the anti-CXCL16 group than the control group. Histologic examination showed that anti-CXCL16 antibody significantly reduced tumor vessel formation and decreased macrophage infiltration in both intra- and peri-tumoral area. Collectively, treatment of anti-CXCL16 antibody reduced tumor growth by inhibiting macrophage and MDSC infiltration following reduced tumor angiogenesis. To explore the mechanistic insight into the monotherapy of anti-CXCL16 antibody, we further analyzed the metabolic changes. In human tumor tissues, TNBC harboring high expression of CXCL16 showed significant shift of glutamine metabolism pathway-related genes (upregulation of GLS and downregulation of GLUL, GLUD1, and GLUD2) toward accumulating glutamate. For cellular experiments, CXCL16-enriched cancer/macrophage co-cultured conditioned medium (co-CM) or cancer single-cultured conditioned medium (s-CM) were treated to cancer cells, and glutamine and glutamate levels were measured. In MDA-MB-231 cells, co-CM treatment significantly enhanced glutamate/glutamine ratio and anti-CXCL16 antibody significantly decreased it. Consistently, glutamate measures in tumor lysates from TNBC xenograft were lower in the anti-CXCL16 group than the control group. In conclusion, anti-CXCL16 antibody (CLS-A101) inhibited immune suppressive myeloid cell infiltration followed tumor angiogenesis and glutamate productions in cancer cells. These dual actions on both tumor immune microenvironment and cancer cell metabolism enables anti-CXCL16 antibody to be a potential monotherapy for TNBC. Citation Format: Min Joo Kim, Hyun Jin Sun, Geun-Hyung Kang, Seong Keun Kim, Sun Wook Cho. Monotherapy of anti-CXCL16 antibody is a potential therapeutic for macrophage-enriched triple-negative breast cancer by modulating tumor immune microenvironment and glutamine metabolism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5556.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2022
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2016
    In:  Molecular Cancer Research Vol. 14, No. 1_Supplement ( 2016-01-01), p. B61-B61
    In: Molecular Cancer Research, American Association for Cancer Research (AACR), Vol. 14, No. 1_Supplement ( 2016-01-01), p. B61-B61
    Abstract: Metformin, an anti-diabetic drug used in type 2 diabetes treatment, is reported to have therapeutic roles in several human cancers. The present study investigated the Effects of metformin on papillary thyroid cancer (PTC) cell apoptosis and autophagy. Metformin inhibited PTC cell viability and increased cell apoptosis in various doses (0.5-20mM) in two different PTC cell lines (BCPAP and BHP10-3SC). Additionally, metformin-treated PTC cells showed increased LC3B-II with ATG5-ATG12 complex suggesting the induction of autophagy. Interestingly, treatment of autophagy inhibitor, BafA1, enhenced metformin-mediated PTC cell apoptosis. In conclusion, the inhibition of autophagy might enhance the anticancer effects of metformin on PTC cells. Citation Format: Young Shin Song, Eun Young Kim, Hyun Jin Sun, Young Joo Park, Do Joon Park, Sun Wook Cho. Effects of metformin on papillary thyroid cancer apoptosis and autophagy. [abstract]. In: Proceedings of the AACR Special Conference: Metabolism and Cancer; Jun 7-10, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(1_Suppl):Abstract nr B61.
    Type of Medium: Online Resource
    ISSN: 1541-7786 , 1557-3125
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2016
    detail.hit.zdb_id: 2097884-4
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2021
    In:  Cancer Research Vol. 81, No. 13_Supplement ( 2021-07-01), p. 2693-2693
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 81, No. 13_Supplement ( 2021-07-01), p. 2693-2693
    Abstract: Endotrophin (ETP), a cleaved fragment of the C5 domain of the Type VI collagen α3 (Col6α3), has been shown to play pro-tumorigenic roles in breast and liver cancers. However, the ETP actions in tumor microenvironment (TME) is still undetermined. This study aimed to investigate the role and the mechanism of ETP in macrophage-enriched thyroid cancer TMEs. First, the expression of ETP on various human thyroid tissues was studied. Immunohistochemical staining showed that the ETP was expressed in papillary (PTC) or anaplastic (ATC) thyroid cancer tissues but not in benign adenoma or autoimmune thyroiditis. Among 146 PTCs, tumors were divided into two groups according to their ETP expression, ETPlow and ETPHigh. Tumor size was bigger and LN metastasis rates were higher in ETPHigh than ETPlow group. Interestingly, the ETP expression showed positive correlations with the CD163-positive macrophages in thyroid tumors. To clarify the origin of ETP in TME of thyroid cancer, xenograft tumor from FRO (ATC) cells was co-stained with anti-ETP and anti-CD11b antibodies. Immunofluorescent staining showed that the expression of ETP and CD11b-postive macrophages were co-localized in the peritumoral area. Moreover, CD163+ cells, as a marker of M2-type macrophage, were co-localized with ETP+ cells. Additionally, human monocytic THP-1 cells were treated with conditioned media (CM) from FRO or BCPAP cells (designated FRO-CM or BCPAP-CM) and demonstrated that ETP expression was more up-regulated in the FRO-CM or BCPAP-CM treated group than in the control group. Collectively, ETP produced from M2-type macrophages in thyroid cancer microenvironments. Next, the pro-tumorigenic functions of ETP has been studied. CMs from co-cultures of FRO or BCPAP cells with THP-1 cells were harvested and treated to FRO or BCPAP cells. Treatment of CMs from co-cultures increased cell migration potentials than that of the single cell alone, and these effects were reduced by anti-ETP neutralizing antibody, indicating that ETPs play essential role in macrophage-induced tumor cell migration potentials. Moreover, MMP-9 and MMP-14, the candidates of Col6α3 protease to produce ETP were increased in THP-1 cells by treatment of CM. Additionally, treatment of CMs from MMP-9 or MMP-14 inhibitor-treated co-cultures of FRO and THP-1 cells decreased cancer cells migration potentials than the control CMs, and these effects were recovered by treatment of ETP. Finally, the RNA-seq dataset of human thyroid cancer showed that higher expressions of ETP positively correlated with macrophage-related genes such as CD163 and MMPs including MMP-9 and MMP-14. In conclusion, macrophage contributes ETP productions by modulating MMP expressions and ETP supports pro-metastatic potentials of human thyroid cancer cells in TMEs. Thus ETP can be a good therapeutic target for macrophage-enriched advanced thyroid cancers Citation Format: Hyo Shik Shin, Hana Kim, Young Shin Song, Hyun Jin Sun, Young Mi Whang, Jiyoung Park, Do Joon Park, Young Joo Park, Sun Wook Cho. Macrophage-derived endotrophin supports tumor migration potentials in thyroid cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2693.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2017
    In:  Cancer Research Vol. 77, No. 13_Supplement ( 2017-07-01), p. 3733-3733
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 77, No. 13_Supplement ( 2017-07-01), p. 3733-3733
    Abstract: Objectives: 18F-fluorodeoxyglucose (FDG), an analogue of glucose, provides valuable functional information based on the increased glucose uptake and glycolysis in malignant tumor cells. Although both glucose transporter-1 (GLUT-1) and hexokinase2 (HK2) activity have been considered to associate with FDG uptake, the molecular mechanisms that determine FDG uptake are still largely unknown. Adenine nucleotide translocase 2 (ANT2) in the mitochondria inner membrane was reported to relate with tumor malignancy. We investigated the correlation between FDG uptake and Glut-1, HK2, and ANT2 expression in thyroid cancers throughout various spectrums of differentiation status. Methods: N-thy-ori (normal human thyroid cells), WRO (follicular cancer), BHP10-3 and TPC-1 (papillary cancer), and FRO (anaplastic cancer) were used for this research. GLUT-1, HK2, and ANT2 expressions were measured by western blot. ANT2 siRNAs and pcDNA3.1-ANT2 vectors were used to modify ANT2 expression. FDG uptakes were measured in thyroid cells and human embryonic kidney cells (293FT) with HK2 or ANT2 transfection. For patient tissue analysis, 95 thyroid tissue-array cores were evaluated, and which are classified 36 as normal, 44 as poorly differentiated (PD), and 15 as anaplastic thyroid cancer (ATC). ANT2 expression was measured by immunostaining, scored from 1 to 5. Results: FDG uptake in thyroid cancer cells was increased in anaplastic and poorly differentiated cells (P & lt;0.001). GLUT-1 expression was higher in both TPC-1 and FRO than other cells. Whereas, HK2 was expressed only in cancer cells. ANT2 was expressed only in FRO cells and the highest FDG accumulation was also observed in FRO. ANT2 siRNA showed decreased FDG uptake (0.55-fold) and ANT2 overexpression increased FDG uptake (1.7-fold). In 293FT cells, HK2 and ANT2 transfection increased FDG uptake (P & lt;0.01). PD tissues (mean = 41.7, SD = 19.7) and ATC (mean = 48.0, SD = 25.6) tissues from patients showed higher ANT2 expression than normal (P & lt;0.05). Conclusion: We showed that ANT2 was expressed only in anaplastic thyroid cancer cells, and this was related to FDG uptake. Higher level of ANT2 expression was observed in dedifferentiated cancer, and this indicates that ANT2 can be used as a marker of malignancy in thyroid cancer. Citation Format: Chul-Hee Lee, Hyewon Youn, Seock-Jin Chung, Ha Kim, Cho Rong Park, Mi Jeong Kim, Young Joo Park, Sun Wook Cho, Keon Wook Kang, June-Key Chung. Adenine nucleotide translocase2 mediates 18F-FDG uptake in dedifferentiated thyroid cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3733. doi:10.1158/1538-7445.AM2017-3733
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2017
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2013
    In:  Cancer Research Vol. 73, No. 3_Supplement ( 2013-02-01), p. B23-B23
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 3_Supplement ( 2013-02-01), p. B23-B23
    Abstract: Introduction: Tumor associated macrophages (TAMs) play a pivotal role in tumoriogenesis of human cancers, including advanced thyroid cancers. A recent study demonstrated that the increased density of TAMs was positively associated with lymph node (LN) metastasis in papillary thyroid cancer (PTC). The purpose of this study was to investigate the functional role of TMA in PTC. Method: Immunohistochemistry with anti-CD68 antibody was performed in 35 PTC patients who had LN metastasis. Co-culture of human PTC (SNU-790) cells and activated human monocytes (THP-1) by macrophage-colony stimulating factor (M-CSF, 50ng/ml) were performed and cell survival rates were analyzed by MTT assay. Result: Among 35 patients, 9 were male and 26 were females. Mean age was 48.9 ± 13.4 years and mean tumor size was 0.94 ± 0.51 cm. Twenty six (74.2%) patients had extrathyroidal invasion. Immunohistochemical staining of primary tumor showed that the expression of CD68 was presence in 3~15% of the peri- and intratumoral areas in all cases, while there was no positivity in normal thyroid tissue adjacent to tumors. In vitro stimulation of THP-1 cells with M-CSF showed significant increase of IL-10 by 7~8 fold compared to vehicle treated cells. Co-culture of SNU-790 cells with M-CSF stimulated THP-1 cells showed higher survival rates than control. Conclusions: TAMs exist in invasive human PTC specifically in intratumoral areas. Activated human monocytes, representing TAM phenotypes support tumor cell survival. Collectively, TAMs may have a functional role in tumor microenvironment of human PTC. Citation Format: Sun Wook Cho, Hye Sook Min, Seunwhan Kim, Kyung Won Kim, Do Joon Park, Young Joo Park. Tumor-associated macrophages in human papillary thyroid cancer. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Invasion and Metastasis; Jan 20-23, 2013; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2013;73(3 Suppl):Abstract nr B23.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...